Radyo Natin

China approves Sinovac use for children aged 3-17 years old

Image source: PNA
The Sinovac vaccine also known as CoronaVac developed by Sinovac Biotech Ltd has been approved by China for emergency use for children aged three to 17 years old, said Chinese Embassy in Manila on Tuesday, July 20.
According to the statement given by the Embassy, the authorization is based on Phase III clinical trial data that suggest CoronaVac is "at least 98.9 percent effective in producing antibodies, a higher efficacy than in the population over 18 years old."
It also said that the study conducted by researchers has involved 180 volunteers within the age group.
Based on the result, the development of antibodies is between 98.9 percent to 100 percent which will depend on the dosage after the administration of the second shot.
"Sinovac vaccine's amount of neutralizing antibody was close to the level recorded 28 days after being vaccinated and remained significantly higher than the level recorded in adults and the elderly in the same period," according to its website.
Also, the website said that this indicates that CoronaVac has stable and good immunogenicity among the children and adolescent population, recording better results compared to those in people aged 18 and above.
In February 2021, the Philippines approved an emergency use authorization (EUA) to Sinovac's jab for healthy individuals aged 18 to 59.
On July 7, the said Chinese company filed an amendment of their EUA to include children three to 17 years old to allow the given age for vaccination, however, the country's Food and Drug Administration has no announcement yet regarding their decision on this matter.

Last Modified: 2021-Jul-22 18.49.54 UTC+0800